Analytical Data
-
Gene name
TACR3
- Application
-
Alternative Names
NK3R; NK3-R; TAC3RL; Neurokinin Beta Receptor; Neurokinin B receptor
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P47937
-
Expression Region
Asn347~Ser452
-
Molecular Weight
18kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TACR3, or Tachykinin Receptor 3, is a member of the tachykinin family of neuropeptide receptors, primarily known for its role in mediating various physiological functions, including pain perception, neurogenic inflammation, and the regulation of anxiety and depression. The receptor is activated by neuropeptides such as neurokinin B, which have been implicated in several neuropsychiatric disorders. Research on TACR3 has gained traction due to its potential as a therapeutic target for conditions like dysmenorrhea, depression, and metabolic disorders. The reconstitution of TACR3 in recombinant systems allows for detailed pharmacological characterization and the exploration of its signaling pathways, revealing insights into its functional dynamics. The ability to study TACR3 in a controlled environment aids in understanding its role in health and disease, and assists in the development of specific modulators that could lead to innovative treatments. As explorations into the receptor’s structure-function relationships advance, TACR3 emerges as a pivotal focus in neuropharmacology, underscoring the necessity for continued research into its biological roles and therapeutic potentials.
